ResMed Inc (ASX: RMD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResMed Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $17.02 billion
P/E Ratio 29.69
Dividend Yield 1.04%
Shares Outstanding 1.47 billion
Earnings per share 0.604
Dividend per share 0.29
Year To Date Return 8.11%
Earnings Yield 3.37%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResMed Inc (ASX: RMD)
    Latest News

    A man sees some good news on his phone and gives a little cheer.
    Healthcare Shares

    ResMed share price jumps almost 7% on stellar quarterly performance

    ResMed shareholders will be sleeping soundly tonight after this update.

    Read more »

    Man sits smiling at a computer showing graphs
    Earnings Results

    ResMed shares on watch after smashing Q2 expectations

    This sleep treatment company was in fine form during the second quarter.

    Read more »

    Business woman watching stocks and trends while thinking
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    Here's what to expect on the ASX 200 before the long weekend.

    Read more »

    A businessman hugs his computer and smiles.
    Growth Shares

    2 ASX 200 shares to buy in 2024 and hold for the next 10 years

    Much can happen in a decade, but these are the businesses I believe are well set to grow over that…

    Read more »

    Contented looking man leans back in his chair at his desk and smiles.
    Blue Chip Shares

    Experts tip very big returns from these outstanding ASX 200 blue chip shares

    These two shares are arguably among the best the market has to offer.

    Read more »

    A man sits bolt upright watching something intently on his television.
    Share Market News

    3 things ASX investors should watch this week

    eToro's Josh Gilbert picks out the biggest developments to keep an eye on for the health of your portfolio.

    Read more »

    A man sitting at his dining table looks at his laptop and ponders the CSL balance sheet and the value of CSL shares today
    Broker Notes

    Top brokers name 3 ASX shares to buy next week

    Brokers gave the thumbs up to these ASX shares last week. Why are they bullish?

    Read more »

    A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
    Blue Chip Shares

    Goldman Sachs says these blue chip ASX 200 shares are top buys

    These shares could be in the buy zone according to the broker.

    Read more »

    A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
    Healthcare Shares

    Is the ResMed share price in the buy zone ahead of next week's update?

    This sleep treatment company's eagerly anticipated Q2 update is coming next week.

    Read more »

    Two brokers analysing stocks.
    Broker Notes

    Top brokers name 3 ASX shares to buy today

    Here's what brokers are recommending as buys this week.

    Read more »

    a man with a wide, eager smile on his face holds up three fingers.
    Growth Shares

    These 3 ASX 200 shares could rise 20% to 40%

    Analysts are tipping these shares to deliver very strong returns.

    Read more »

    Young woman using computer laptop with hand on chin thinking about question, pensive expression.
    Healthcare Shares

    Are ResMed shares still undervalued in 2024?

    Is this beaten down sleep treatment giant still cheap?

    Read more »

    Frequently Asked Questions

    Yes. As well as being listed on the ASX since November 1999, ResMed trades on the New York Stock Exchange under the ticker code NYSE: RMD.

    Yes, historically ResMed pays unfranked quarterly dividends each year. It does not offer a dividend reinvestment plan.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    07 Feb 2024 $0.0517 0.00% Interim 14 Mar 2024
    08 Nov 2023 $0.0528 0.00% Interim 14 Dec 2023
    16 Aug 2023 $0.0524 0.00% Final 21 Sep 2023
    10 May 2023 $0.0460 0.00% Interim 15 Jun 2023
    08 Feb 2023 $0.0444 0.00% Interim 16 Mar 2023
    09 Nov 2022 $0.0466 0.00% Interim 15 Dec 2022
    17 Aug 2022 $0.0445 0.00% Final 22 Sep 2022
    11 May 2022 $0.0429 0.00% Interim 16 Jun 2022
    09 Feb 2022 $0.0410 0.00% Interim 17 Mar 2022
    10 Nov 2021 $0.0403 0.00% Interim 16 Dec 2021
    18 Aug 2021 $0.0412 0.00% Final 23 Sep 2021
    12 May 2021 $0.0354 0.00% Interim 17 Jun 2021
    10 Feb 2021 $0.0352 0.00% Interim 18 Mar 2021
    11 Nov 2020 $0.0378 0.00% Interim 17 Dec 2020
    19 Aug 2020 $0.0379 0.00% Final 24 Sep 2020
    13 May 2020 $0.0423 0.00% Interim 18 Jun 2020
    12 Feb 2020 $0.0406 0.00% Interim 19 Mar 2020
    06 Nov 2019 $0.0396 0.00% Interim 12 Dec 2019
    14 Aug 2019 $0.0403 0.00% Final 19 Sep 2019
    08 May 2019 $0.0371 0.00% Interim 13 Jun 2019
    06 Feb 2019 $0.0365 0.00% Interim 14 Mar 2019
    07 Nov 2018 $0.0356 0.00% Interim 13 Dec 2018
    15 Aug 2018 $0.0357 0.00% Final 20 Sep 2018
    09 May 2018 $0.0326 0.00% Interim 14 Jun 2018
    07 Feb 2018 $0.0315 0.00% Interim 15 Mar 2018
    08 Nov 2017 $0.0320 0.00% Interim 14 Dec 2017
    16 Aug 2017 $0.0308 0.00% Final 21 Sep 2017
    10 May 2017 $0.0313 0.00% Interim 15 Jun 2017
    08 Feb 2017 $0.0303 0.00% Interim 16 Mar 2017
    09 Nov 2016 $0.0303 0.00% Interim 15 Dec 2016
    17 Aug 2016 $0.0300 0.00% Final 22 Sep 2016
    18 May 2016 $0.0291 0.00% Interim 16 Jun 2016
    09 Feb 2016 $0.0295 0.00% Interim 17 Mar 2016
    17 Nov 2015 $0.0292 0.00% Interim 17 Dec 2015

    RMD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About ResMed Inc

    ResMed Inc (ASX: RMD) is a global leader in sleep technology. It develops, manufactures, and distributes medical devices – such as flow generators, CPAP masks, and accessories – and cloud-based software applications that diagnose, treat, and manage a range of respiratory disorders including sleep apnea, chronic obstructive pulmonary disease (COPD), and neuromuscular disease.

    It also provides software platforms to support professionals and caregivers to help patients in an out-of-hospital setting. The company operates in more than 140 countries, with manufacturing facilities in Australia, Singapore, France, and the United States. ResMed was established in Australia in 1989 but is now based in San Diego in the United States.

    RMD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    21 Feb 2024 $27.52 $0.09 0.33% 1,143,513 $27.70 $27.76 $27.31
    20 Feb 2024 $27.43 $-0.10 -0.36% 1,037,664 $27.53 $27.80 $27.42
    19 Feb 2024 $27.53 $-0.25 -0.90% 1,408,509 $27.75 $27.76 $27.47
    16 Feb 2024 $27.78 $-0.18 -0.64% 1,389,435 $28.25 $28.25 $27.78
    15 Feb 2024 $27.96 $0.19 0.68% 1,574,169 $27.75 $28.06 $27.67
    14 Feb 2024 $27.77 $-0.14 -0.50% 1,685,383 $27.70 $27.86 $27.54
    13 Feb 2024 $27.91 $-0.22 -0.78% 1,748,561 $28.18 $28.18 $27.87
    12 Feb 2024 $28.13 $-0.39 -1.37% 1,476,074 $28.23 $28.29 $28.04
    09 Feb 2024 $28.52 $-0.11 -0.38% 2,040,396 $28.29 $28.61 $28.09
    08 Feb 2024 $28.63 $-0.55 -1.88% 1,326,323 $28.76 $28.82 $28.44
    07 Feb 2024 $29.18 $-0.12 -0.41% 1,548,014 $29.62 $29.65 $29.08
    06 Feb 2024 $29.30 $-0.23 -0.78% 1,234,716 $29.41 $29.45 $29.15
    05 Feb 2024 $29.53 $0.10 0.34% 2,617,782 $29.39 $29.56 $29.29
    02 Feb 2024 $29.43 $0.28 0.96% 1,897,355 $29.49 $29.58 $29.33
    01 Feb 2024 $29.15 $-0.05 -0.17% 2,633,980 $29.10 $29.32 $28.92
    31 Jan 2024 $29.20 $0.25 0.86% 2,075,580 $29.03 $29.20 $28.81
    30 Jan 2024 $28.95 $0.51 1.79% 3,029,826 $28.87 $29.07 $28.73
    29 Jan 2024 $28.44 $-0.01 -0.04% 3,845,950 $29.05 $29.16 $28.39
    25 Jan 2024 $28.45 $1.70 6.36% 4,571,634 $28.37 $28.87 $27.87
    24 Jan 2024 $26.75 $-0.06 -0.22% 1,571,606 $26.94 $26.98 $26.61
    23 Jan 2024 $26.81 $0.30 1.13% 2,071,027 $26.84 $27.12 $26.78

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Peter Craig Farrell Non-Executive DirectorNon-Executive Chairman Jul 2002
    No profile reported in Annual Report.
    Mr Ronald R Taylor Non-Executive Director Jan 2005
    Mr Taylor is a director of Actavis, Inc. and Red Lion Hotels Corp. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation. In 1987, Mr. Taylor founded Pyxis Corporation where he served as chairman, president, and chief executive officer until its purchase by Cardinal Health, Inc., in 1996.
    Mr Richard Sulpizio Non-Executive Director Aug 2005
    Mr Sulpizio has served as president and chief executive officer of Qualcomm Enterprise Services. He currently serves as a senior advisor to Qualcomm Enterprise Services. Mr Sulpizio held various positions with Qualcomm during his 20-year tenure there, including president and chief operating officer. He served as a member of Qualcomm's board of directors from 2000 until 2007.
    Mr Michael J Farrell Chief Executive OfficerExecutive Director Mar 2013
    Mr Farrell was foundation director of Biomedical Engineering at the University of New South Wales where he currently serves as a visiting professor and as chairman of the UNSW Centre for Innovation and Entrepreneurship. Since 2005, Dr Farrell has been a director of NuVasive, Inc. He also serves as the non-executive chair of QRxPharma.
    Ms Carol Burt Non-Executive Director Aug 2014
    No profile reported in Annual Report.
    Ms Karen Ruth Drexler Non-Executive Director Nov 2017
    No profile reported in Annual Report.
    Mr Jan De Witte Non-Executive Director May 2019
    Mr De Witte is the chief executive officer and member of the board of directors of Barco NV.
    Ms Harjit Gill Non-Executive Director Nov 2018
    No profile reported in Annual Report.
    Mr John Hernandez Non-Executive Director Nov 2021
    No profile reported in Annual Report.
    Mr Desney Tan Non-Executive Director Nov 2021
    No profile reported in Annual Report.
    Brett A. Sandercock Chief Financial Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No Top 20 Shareholder 0 0.00%

    Profile

    since

    Note